#Engauge digitizer hazard ratio windows#
Studies that did not meet all inclusion criteria were excluded.Īll the statistical analyses were performed using Stata/SE 10.0 for Windows (Stata Corporation, College Station, TX, USA). Publications re-using datasets from the same population, the article with more extracted details was included. When multiple NSCLC cohorts were used to validate the same results in one paper, groups using the same detection methods were merged as one group. There were no limitations on language nor on patient numbers.
#Engauge digitizer hazard ratio full#
The published studies that were included in this meta-analysis should meet the following criteria: (1) the histologic type of the tumors was NSCLC (2) they assessed the relationship between SOX2 expression and clinicopathological features and/or survival and only full peer reviewed papers have been published as full texts. Search terms were “lung cancer” and “SOX2”. The electronic database of PubMed was searched for studies that investigated the association of clinicopathological parameters and prognosis with SOX2 expressionin NSCLC to be included in the present meta-analysis upto May 14, 2013. Considering the putative role of SOX2 in the prognosis and prediction of outcome in NSCLC, a meta-analysis was conducted to determine the association between SOX2 and common clinical and pathologic features of NSCLC.
These conflicting results on the detection, clinical pathologic features and progression of SOX2 positive expression could indicate limited availability of samples resulting in variations in the clinical significance of the results and the need for overall analysis. SOX2 gene amplification is frequently up-regulated in NSCLC, and is associated with poor prognosis, but recently results show that high SOX2 levels predict better outcome in NSCLC. Recently, a number of studies have reported the contribution of SOX2 to tumorigenesis and itscorrelation with clinical progression of various types of tumors, including human breast cancer, rectal cancer, prostate cancer and NSCLC. Over-expression of SOX2 in NSCLC cells stimulates cellular migration and anchorage-independent growth while SOX2 knockdown impairs cell growth –. SRY (sex determining region Y)-box 2, also known as SOX2, is one of the key transcriptional factors that control the unique properties of stem cells self-renewal and pluripotency, and play a critical role inmaintaining the stem cell-like phenotype in cancer cells –. Recent advances have provided provocative insights in the biology of NSCLC that may result in the discovery of biological markers, that are urgently needed for guidance on postoperative surveillance and therapeutic decisions. Though significant diagnostic and therapeutic improvements have been made for NSCLC, the prognosis is still suboptimal, with an overall five-year survival rate of less than 15%.
Among all LC cases, NSCLC accounts for approximately 85%. The main types of LC are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC).
Lung cancer (LC) is the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide.
0 kommentar(er)
